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The major finding of the trial was that there was no significant difference in hemoglobin A1c at 24 months as described in the primary outcome. A small number of differences in secondary outcomes were found but were not felt to be clinically highly significant. Comments -1. The paper is very clearly written. Limitations of the study are clearly described. The findings are in keeping with other reports of retrospective analyses and smaller single centre studies. 2. The written description of the study results is combined with the tables. I feel it would be clearer if the text description of the results was combined instead of being scattered among the tables. Where differences were found between groups, it would be helpful to describe which group had a better or worse outcome with each outcome. 3. The authors point out that differences in secondary outcomes are to be interpreted with caution as there were no adjustments made for multiple testing. The reasoning for not using correction for multiple testing should be included in the manuscript or the analyses should be presented with a correction for multiple testing.
4. In the sample size description, and effect size of 0.4 (A1c difference of 5 mmmol/mol) was chosen. It would be helpful to understand the reasons for the choice of this effect size. 5. In the discussion, the terms "commissioners and service leads" are used. It would be helpful to use more generalizable terms to describe these roles 6. Severe adverse events were reported but it is not clear if these were diabetes-related 7. It would be helpful if the units of NHS use were explained in Table 9 .
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GENERAL COMMENTS
This paper by Gregory et al. reports the results of the DECIDE randomized trial which compared home and hospital initiation of treatment for type 1 diabetes in children. Because of the randomized design and relatively large sample size, this has the potential to be an interesting paper. However, there are a number of flaws in the analysis and interpretation of the results that need to be addressed.
-It is unclear whether the original hypothesis for this study was that there would be a difference between the groups or whether they would be equivalent. The objective as stated in the abstract is to test whether home management is better. But in the introduction, they write that they hypothesized that there would be no difference. If the purpose is to demonstrate equivalence, they should have utilized an equivalence design.
-The authors state that a primary endpoint of HbA1c at 24 months was chosen because patients would not have endogenous insulin secretion by that time, which may be valid. However, it seems unlikely that the setting of initial treatment would still have an effect 2 years later, and that it might have been preferable to choose an earlier time point.
-In the description of the power calculation, it is not clear whether power was calculated for a cross-sectional comparison at 24 months, or for a change from baseline. If the former, this is not consistent with the primary outcome results in table 2.
-The statistical methods section states that their primary analysis was a complete case analysis. For HbA1c, there was not much missing data, so this could be viewed as appropriate. But for the secondary outcomes, there is quite a bit of missing data. They should use mixed models rather than repeated measures ANCOVA to avoid bias in the presence of missing data (which also assumes that the data are not missing not at random).
-Description of imputation procedures should be clarified in the methods. It was not until later in the paper that I realized that they were performing imputation by using all possible replacements of HbA1c values. This is also not a standard imputation procedure and needs justification.
-The statistical methods section does not state what analysis method was used for the primary outcome.
-For the secondary analyses, the methods section states that the groups were compared using separate linear regressions at different time points. Why was linear regression used and not a typical two group comparison? Also, separate models at the different time points will potentially inflate the type 1 error rate.
-The statistical methods section states that secondary analyses were corrected for clustering within a center. Why wasn't this done for the primary outcome? How did they identify whether clustering was significant enough to need correction? How was the correction performed?
-The analysis of SAE's is flawed. Logistic regression requires that all patients have exactly the same amount of follow up and there is no censoring. Also, patients could have more than one SAE, so Poisson regression with an offset for follow-up time would be a better choice. Again, how did they detect/adjust for clustering? The OR from the logistic regression is reported without any information about the direction of the effect (i.e., the reference group). Finally, the SAE data should not be buried in the supplemental material. It appears that there was a higher rate of SAE's in the home arm.
-In table 1, be consistent with choice of decimal symbol.
-In table 2 (and subsequent tables), what is "effect"? This should be explained in the methods.
-Page 11, paragraph starting line 13 needs more explanation.
Marginal differences in what?
-The differential effect in self esteem is in one direction at month 1 and the other at month 24 -it's hard to know what to make of this.
-In the participant flow diagram, it's unusual to show centers that did not participate. In the box that describes the patients that were not recruited, some of the bullets under "does not meet inclusion criteria" are exclusion criteria and some are not. The only reason given for withdrawal is "other," which is not informative.
-There is quite a bit of missing data for the questionnaires, and the rates of completion are lower in the hospital group. This is not addressed in the manuscript. Statistical methods that are unbiased in the presence of missing data need to be used.
-In figure 2 , are the stars outliers?
- Tables 3, 4 , and 5 -reporting results on the square root scale is not interpretable. Also, there is too much information in these 3 tables and the presentation is confusing (e.g., reporting "time-visit interaction"). The ordering of results is different for children and parents.
-The ICC is reported in table 4 but not table 5. No explanation or interpretation is given.
-Supplemental table 1 -it's odd that all the percentiles for diabetes knowledge are exactly the same in the two groups.
-Results in supplemental table 2 are reported as "how satisfied have you been with care while your child is in the hospital?" But half the children are not in the hospital. More importantly, the satisfaction rates are lower in the home group. Is this because they did not understand the question or are they truly lower? This is not discussed.
VERSION 1 -AUTHOR RESPONSE
Response to Reviewer 1 comments:
Comment Response
1. The paper is very clearly written. Limitations of the study are clearly described. The findings are in keeping with other reports of retrospective analyses and smaller single centre studies.
We thank the reviewer for these comments 2. The written description of the study results is combined with the tables. I feel it would be clearer if the text description of the results was combined instead of being scattered among the tables. Where differences were found between groups, it would be helpful to describe which group had a better or worse outcome with each outcome.
We have followed the author guidance to embed tables within the text but we are happy to take editorial advice if the formatting should be amended. We have made the results section clearer.
3. The authors point out that differences in secondary outcomes are to be interpreted with caution as there were no adjustments made for multiple testing. The reasoning for not using correction for multiple testing should be included in the manuscript or the analyses should be presented with a correction for multiple testing.
This has been corrected. The statistical analysis section now states: 'Only p<0.001 can be considered statistically significant for all following analyses.' With the relevant comment 'to interpret the differences with caution' in the results section removed.
4. In the sample size description, and effect size of 0.4 (A1c difference of 5 mmmol/mol) was chosen. It would be helpful to understand the reasons for the choice of this effect size.
The reason for the choice of the effect size was based on the Cochrane Systematic review 3 and the Canadian study 4 which showed a difference of 0.7% in mean HbA1c at two years, (better outcome for those in the home management arm). We have added the additional reference to the sample size section on page 7.
5. In the discussion, the terms "commissioners and service leads" are used. It would be helpful to use more generalizable terms to describe these roles.
Recognising the differences in the meaning in these terms internationally, we have amended this term to read "those responsible for the provision of health services" 6. Severe adverse events were reported but it is not clear if these were diabetes-related
We recognise that we have not presented the SAE results clearly. Therefore, we have provided an additional table with more detail in the Supplementary material (Table 10) . We have also provided additional text in the manuscript page 19.
7. It would be helpful if the units of NHS use were explained in Table 9 .
The units of NHS use are detailed in Table 11 , we have added text to the main manuscript to make this clear.
Response to Reviewer 2 comments:
Comment Response 1. It is unclear whether the original hypothesis for this study was that there would be a difference between the groups or whether they would be equivalent. The objective as stated in the abstract is to test whether home management is better. But in the introduction, they write that they hypothesized that there would be no difference. If the purpose is to demonstrate equivalence, they should have utilized an equivalence design.
We apologise for the confusion caused. The objective in the abstract is correct. We have amended the line in the introduction to correct the hypothesis. The study was designed to demonstrate difference.
2. The authors state that a primary endpoint of HbA1c at 24 months was chosen because patients would not have endogenous insulin secretion by that time, which may be valid. However, it seems unlikely that the setting of initial treatment would still have an effect 2 years later, and that it might have been preferable to choose an earlier time point.
The study design was based on the only international trial of home .v. hospital management at the time, which suggested that home management was better, reflected in significantly lower HbA1c at 24 months follow up. 3. In the description of the power calculation, it is not clear whether power was calculated for a cross-sectional comparison at 24 months, or for a change from baseline. If the former, this is not consistent with the primary outcome results in table 2.
The power calculation was based on a cross sectional comparison at 24 months. The primary analysis was also based on a cross-sectional analysis of the difference between arms at 24 months, consistent with the design, but was also adjusted for baseline HbA1c thus gaining additional statistical power when the correlation between baseline and follow-up is greater than 0. This uses ANCOVA methodology and is not the same as change from baseline analysis.
4. The statistical methods section states that their primary analysis was a complete case analysis. For HbA1c, there was not much missing data, so this could be viewed as appropriate. But for the secondary outcomes, there is quite a bit of missing data. They should use mixed models rather than repeated measures ANCOVA to avoid bias in the presence of missing data (which also assumes that the data are not missing not at random).
Apologies for the poor description of these models. The individual timepoint models are mixed models. The repeated measures analyses use generalised linear models.
5. Description of imputation procedures should be clarified in the methods. It was not until later in the paper that I realized that they were performing imputation by using all possible replacements of HbA1c values. This is also not a standard imputation procedure and needs justification.
The description in the statistical analysis section has been updated to make this clearer. We had central laboratory data and routine trial site measurements of HbA1c. The sensitivity analysis replaces missing laboratory data with available routine trial site HbA1c measurements taken at the relevant timepoints. This is not imputation but a merging of different sources of the same measurement.
6. The statistical methods section does not state what analysis method was used for the primary outcome.
We have provided clarity in the statistical methods section, it states "a mixed 2-level hierarchical linear model."
7. For the secondary analyses, the methods section states that the groups were compared using separate linear regressions at different time points. Why was linear regression used and not a typical two group Linear regression with arm as covariate provides an estimate for the difference in means between arms for that dependent variable. The type 1 error rate is inflated by the multitude of comparison? Also, separate models at the different time points will potentially inflate the type 1 error rate.
tests undertaken but all are necessary to describe the action of the intervention properly.
8. The statistical methods section states that secondary analyses were corrected for clustering within a center. Why wasn't this done for the primary outcome? How did they identify whether clustering was significant enough to need correction? How was the correction performed?
The primary analysis was corrected for clustering. The statistical analysis section states for b: 'analysis was corrected for any clustering of outcomes within centres by using a mixed 2-level hierarchical linear model.'
9. The analysis of SAE's is flawed. Logistic regression requires that all patients have exactly the same amount of follow up and there is no censoring. Also, patients could have more than one SAE, so Poisson regression with an offset for follow-up time would be a better choice. Again, how did they detect/adjust for clustering? The OR from the logistic regression is reported without any information about the direction of the effect (i.e., the reference group). Finally, the SAE data should not be buried in the supplemental material. It appears that there was a higher rate of SAE's in the home arm.
We recognise that logistic regression was inappropriate for the analyses of SAEs. In response to the comment above regarding providing more details of SAEs i.e. were the SAEs diabetes related, we have provided an additional table (Supplementary material, Table 10 ). We have removed the logistic regression analyses and feel that the descriptive detail provides more useful information. Using this approach it illustrates that there is little difference between arms.
10. In This refers to Difference in Means. The heading in all tables has been altered to make it clearer.
12. Page 11, paragraph starting line 13 needs more explanation.
Marginal differences in what?
This wording has been removed because we recognise that marginal differences are probably as a result of multiple testing.
13. The differential effect in self esteem is in one direction at month 1 and the other at month 24 -it's hard to know what to make of this.
We agree, and as above, regarding multiple testing, we have added a definition to state that 'only p<0.001 can be considered statistically significant for all following analyses.'
Given the change in definition of statistical significance, we no longer report on this.
14. In the participant flow diagram, it's unusual to show centers that did not participate. In the box that describes the patients that were not recruited, some of the bullets under "does not meet inclusion criteria" are exclusion criteria and some are not. The only reason given for withdrawal is "other," which is not informative.
We have amended the participant flow diagram (Figure 1) as suggested, deleting the centres who did not participate, and have provided clarity over those who did, and did not meet the inclusion criteria.
We have provided clarity for the reason for withdrawal, which was stated as "family reasons".
15. There is quite a bit of missing data for the questionnaires, and the rates of completion are lower in the hospital group. This is not addressed in the manuscript. Statistical methods that are unbiased in the presence of missing data need to be used.
There is a lower completion of Child questionnaires in the hospital arm compared to the home arm but we do not consider this a major concern (NB, the maximum difference in retention is 8.1%points). Statistical methods, which are now fully listed (see point above).
16. In figure 2 , are the stars outliers?
The stars are extreme outliers, which are outside twice the length of the relevant whisker. We have added a legend to Figure 2 for clarity.
17. Tables 3, 4 , and 5 -reporting results on the square root scale is not interpretable. Also, there is too much information in these 3 tables and the presentation is confusing (e.g., reporting "time-visit interaction"). The ordering of results is different for children and parents.
All descriptive reporting of Issues in Coping with IDDM is consistent across Comment 9: There was almost a 50% increase in the number of hypo-or hyperglycemia events. This needs proper statistical comparison, accounting for follow-up time, not logistic regression as was performed in the original analysis. I don't believe the current presentation is sufficient. If significant differences are found, this needs to be discussed in the paper and possibly the abstract.
Comment 17: I understand that reporting the visit-arm interaction is necessary, but there is little explanation or interpretation of table 3. Most readers will not be able to interpret the combination of main effects and interaction presented in Table 3 . 
GENERAL COMMENTS
My comments have been adequately addressed.
Reviewer comment Author response Comment 9: There was almost a 50% increase in the number of hypoor hyperglycemia events. This needs proper statistical comparison, accounting for follow-up time, not logistic regression as was performed in the original analysis. I don't believe the current presentation is sufficient. If significant differences are found, this needs to be discussed in the paper and possibly the abstract.
The follow-up time in both arms was the same (24 months) for the collection of SAE data so an analysis accounting for time is not required. Events are clustered within patients so the tables in the supplementary material provide the data by event and by patient in accordance with CONSORT. 95% Confidence intervals have now been calculated for the difference in proportions of events and patients reporting SAEs for the aid of interpretation only. Since only the primary outcome of the trial was powered, hypothesis tests and p-values for these event rates would be highly misleading. None of the differences indicate that there were significantly higher rates in one arm compared with the other and in the absence of statistical significance we have not referred to this finding in the abstract.
We have also substantially re-drafted the relevant paragraph (see page 19). We hope this addresses the referee's concerns adequately but if not, we will be happy to take further guidance.
Comment 17: I understand that reporting the visit-arm interaction is necessary, but there is little explanation or interpretation of table 3. Most readers will not be able to interpret the combination of main effects and interaction presented in Table 3 .
Further explanation has been provided in the text relating to table 3 and the direction of the self-esteem change has been described.
